Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme

Inclusion Criteria: * Histologically confirmed intracranial glioblastoma multiforme (GBM) * Original diagnosis of low-grade glioma with subsequent histological confirmation of GBM allowed * Recurrent disease * Failed prior radiotherapy * Must require a surgical procedure (gross total or near gross total resection) for tumor removal * Performance status - Karnofsky 60-100% * White Blood Count (WBC) ≥ 3,000/mm\^3 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hemoglobin ≥ 10 g/dL (transfusion allowed) * Serum glutamic oxaloacetic transaminase (SGOT) \< 2 times upper limit of normal (ULN) * Bilirubin \< 2 times ULN * Creatinine \< 1.5 mg/dL * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective barrier contraception during and for ≥ 2 weeks after study participation (for female patients) or for 3 months after study participation (for male patients) * No other malignancy within the past 3 years except nonmelanoma skin cancer or carcinoma in situ of the cervix * No active infection * No other significant uncontrolled medical illness that would preclude study participation * At least 3 weeks since prior interferon * No prior cilengitide * No other prior targeted antiangiogenic treatment (e.g., vatalanib, SU5416, or thalidomide) * No concurrent anticancer immunotherapy * No concurrent routine prophylactic filgrastim (G-CSF) * At least 2 weeks since prior vincristine * At least 3 weeks since prior procarbazine * At least 6 weeks since prior nitrosoureas * No concurrent anticancer chemotherapy * At least 3 weeks since prior tamoxifen * No concurrent anticancer hormonal therapy * See Disease Characteristics * At least 4 weeks since prior radiotherapy * No concurrent anticancer radiotherapy * Recovered from all prior therapies * No more than 3 prior treatments for GBM (1 initial treatment; and treatment for 2 relapses) * For patients who received prior therapy for low-grade glioma, a subsequent surgical diagnosis of high-grade glioma is considered the first relapse * At least 4 weeks since prior investigational agents * At least 4 weeks since prior cytotoxic therapy * At least 3 weeks since other prior non-cytotoxic therapy (e.g., isotretinoin), except radiosensitizers * No other concurrent anticancer therapy * No other concurrent investigational agents